ZyVersa Therapeutics (ZVSA) said newly published data has demonstrated that NLRP3 Inhibition attenuates development of Alzheimers disease pathology and neuroinflammation in a mouse model of AD, thereby attenuating disease progression. The new study data were published in the peer-reviewed journal, Immunity. In the publication, the researchers reported data from studies conducted in a mouse model of Alzheimers disease, murine microglia, and human THP-1 cells. The company noted that these data support the potential of ZyVersa's Inflammasome ASC Inhibitor IC 100 as an effective treatment option for patients with neurodegenerative diseases such as Alzheimer's and Parkinsons diseases.
"These data strengthen support for the potential role for Inflammasome ASC Inhibitor as a treatment for Alzheimers and other neurological diseases, such as Parkinsons disease," said Stephen Glover, ZyVersas Co-founder, Chairman, CEO and President.
Shares of ZyVersa Therapeutics are up 13% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.